Human placental 15-hydroxy-prostaglandin dehydrogenase activity is under fetal genetic control.
Placental 15-hydroxy-prostaglandin dehydrogenase (PGDH type I) was measured in 33 placentae obtained from 1 trizygotic, 7 dizygotic and 8 monozygotic pregnancies. PGDH activity ranged from 0.33 to 4.62 nmol PGF2 alpha metabolized per mg placental protein per min, which was within the range observed in singleton pregnancies. Expressing PGDH activity per mg DNA, offered no advantage over expressing it per mg total protein. PGDH activity differed significantly between the placentae of 6 of the 9 genetically non-identical placental pairs. The placentae of genetically identical twins, on the other hand, showed no difference in PGDH activity between the pairs. The data indicate that the genetic constitution of the fetus determines placental PGDH activity. They also provide us with the first evidence that the variation in prostaglandin catabolizing capacity of the human placenta is not entirely dictated by the maternal endocrine environment, but is under fetal control.
Erwich
J J
JJ
Department of Obstetrics, Leiden University Hospital, The Netherlands.
Keirse
M J
MJ
D000328:Adult; D005260:Female; D005333:Fetus / Q000502:physiology*; D006801:Humans; D006911:Hydroxyprostaglandin Dehydrogenases / Q000235:genetics* / Q000378:metabolism; D010920:Placenta / Q000201:enzymology*; D011247:Pregnancy; D014310:Triplets; D014429:Twins, Dizygotic; D014430:Twins, Monozygotic
D006911:Hydroxyprostaglandin Dehydrogenases; C035859:15-hydroxyprostaglandin dehydrogenase